These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32663622)

  • 21. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
    Bhutani D; Leng S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
    Rybinski B; Kocoglu M
    Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
    Popkova T; Hajek R; Jelinek T
    Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
    Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
    Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
    Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
    Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
    Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
    Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ultrastructural basis of renal pathology in monoclonal gammopathies.
    Santostefano M; Zanchelli F; Zaccaria A; Poletti G; Fusaroli M
    J Nephrol; 2005; 18(6):659-75. PubMed ID: 16358223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging drugs for the treatment of light chain amyloidosis.
    Chakraborty R; Lentzsch S
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):299-317. PubMed ID: 32731778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kidney and liver involvement in monoclonal light chain disorders.
    Pozzi C; Locatelli F
    Semin Nephrol; 2002 Jul; 22(4):319-30. PubMed ID: 12118397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
    Vaxman I; Dispenzieri A; Muchtar E; Gertz M
    Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [AL amyloidosis, from diagnosis to treatment].
    Villesuzanne C; Jaccard A; Nicol M
    Rev Prat; 2020 Dec; 70(10):1137-1141. PubMed ID: 33739663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
    Picken MM
    Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
    Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
    Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
    [No Abstract]   [Full Text] [Related]  

  • 34. Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).
    Ghilardi G; Stussi G; Mazzucchelli L; Röcken C; Rossi D; Gerber B
    Amyloid; 2019 Sep; 26(3):173-174. PubMed ID: 31232114
    [No Abstract]   [Full Text] [Related]  

  • 35. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
    Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
    Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing systemic light-chain amyloidosis.
    Comenzo RL
    J Natl Compr Canc Netw; 2007 Feb; 5(2):179-87. PubMed ID: 17335687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
    Zhang C; Huang X; Li J
    Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of systemic light-chain deposition disease and amyloidosis: a report of three patients with renal involvement.
    Jacquot C; Saint-Andre JP; Touchard G; Nochy D; D'Auzac de Lamartinie C; Oriol R; Druet P; Bariety J
    Clin Nephrol; 1985 Aug; 24(2):93-8. PubMed ID: 3930115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.